

11-224-C100

Monoclonal Antibody to CD45RB Purified Antibody (0.1 mg)

Clone: MEM-55

Isotype: Mouse IgG1

Specificity: The antibody MEM-55 recognizes a siliadase-sensitive epitope of CD45RB, a

180-240 kDa single chain type I membrane glycoprotein, variant of CD45 (CD45RB isoform). CD45RB is expressed on a subset of T lymphocytes, B

lymphocytes, monocytes, macrophages, granulocytes and dendritic cells.

HLDA III; WS Code NL 358 HLDA IV; WS Code NL 2 HLDA V; WS Code T T-151 HLDA V; WS Code T T-CD45.08

Regulatory Status: RUO

Immunogen: Human thymocytes and T lymphocytes.

Species Reactivity: Human, Non-Human Primates

Application: Flow Cytometry

Recommended dilution:2 µg/ml

Immunoprecipitation Western Blotting

Immunohistochemistry (paraffin sections)
No pre-treatment of tissue sections is essential.

Purity: > 95% (by SDS-PAGE)

Purification: Purified by protein-A affinity chromatography

Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Storage / Stability: Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial

label.

Expiration: See vial label

Lot Number: See vial label

Background: CD45RB is an of a receptor-type protein tyrosine phosphatase, CD45 glycoprotein.

CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apoptosis. CD45 isoforms differ in their extracellular domains, whereas they share identical transmembrane and cytoplasmic domains. These isoforms differ in their ability to translocate into the glycosphingolipid-enriched membrane domains and their expression depends on cell type and physiological state of the cell. CD45RB is expressed e.g. in microglia and inflammatory cells.



PRODUCT DATA SHEET

References:

*Townsend KP, Vendrame M, Ehrhart J, Faza B, Zeng J, Town T, Tan J: CD45 isoform RB as a molecular target to oppose lipopolysaccharide-induced microglial activation in mice. Neurosci Lett. 2004 May 13;362(1):26-30.

*Li FJ, Tsuyama N, Ishikawa H, Obata M, Abroun S, Liu S, Otsuyama K, Zheng X, Ma Z, Maki Y, Kawano MM: A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma. Blood. 2005 Apr 15;105(8):3295-302.

*Cosenza-Nashat MA, Kim MO, Zhao ML, Suh HS, Lee SC: CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. Brain Pathol. 2006 Oct;16(4):256-65.

*Dawes R, Petrova S, Liu Z, Wraith D, Beverley PC, Tchilian EZ. Combinations of CD45 isoforms are crucial for immune function and disease. J Immunol. 2006 Mar 15;176(6):3417-25.

*Bijian K, Zhang L, Shen SH: Collagen-mediated survival signaling is modulated by CD45 in Jurkat T cells. Mol Immunol. 2007 Jul;44(15):3682-90.

*Desharnais P, Dupéré-Minier G, Hamelin C, Devine P, Bernier J: Involvement of CD45 in DNA fragmentation in apoptosis induced by mitochondrial perturbing agents. Apoptosis. 2007 Dec 19

*Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987).

*Horejsi V, Angelisova P, Bazil V, Kristofova H, Stoyanov S, Stefanova I, Hausner P, Vosecky M, Hilgert I: Monoclonal antibodies against human leucocyte antigens. II. Antibodies against CD45 (T200), CD3 (T3), CD43, CD10 (CALLA), transferrin receptor (T9), a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74). Folia Biol (Praha). 1988;34(1):23-34.

*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).

*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). *Koethe S, Zander L, Köster S, Annan A, Ebenfelt A, Spencer J, Bemark M: Pivotal advance: CD45RB glycosylation is specifically regulated during human peripheral B cell differentiation. J Leukoc Biol. 2011 Jul;90(1):5-19.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.